What it is:Urinary incontinence (UI) is involuntary loss of urine. It's not a diagnosis so much as a symptom with four different mechanical causes, and the mechanism is what tells you which drug (if any) to reach for.
The core problem:Continence depends on two systems staying in the right state at the right time: the bladder (detrusor)should stay relaxed while filling and contract on command to empty, and the urethral sphinctershould stay closed while filling and open on command to let urine out. UI happens when either one misbehaves, or when the plumbing is fine but the patient can't get to a toilet in time.
What you do about it:Nail down which type you're dealing with using symptom pattern and a couple of targeted tests, start with behavioral therapy in almost every case, then layer on the drug class that matches the broken mechanism.
Think of it as "a pump and a valve."The bladder is the pump, the urethral sphincter is the valve. Overactive pump= urgency incontinence (UUI/OAB), fixed by relaxing the detrusor. Underactive valve= stress incontinence (SUI), fixed by tightening urethral resistance. Valve won't open / pump can't empty= overflow, and no drug for UUI or SUI belongs anywhere near it. Every treatment decision in this chapter traces back to which piece is broken.
Everything downstream, workup and drug choice, depends on correctly bucketing the patient into one of these. Mixed incontinence is just the first two happening together, which is common in older women.
Sphincter loses resistance during ↑ intra-abdominal pressure.
Detrusor contracts inappropriately during storage.
Bladder fills past capacity, urine leaks past a distended, obstructed system.
Nothing wrong with bladder or urethra, the patient just can't get there in time.
Mixed incontinenceis SUI plus UUI together, extremely common and treated by targeting whichever component bothers the patient most. Functional incontinence isn't a bladder or urethra problem at all, so drugs for OAB or SUI won't fix it, the fix is environmental (bedside commode, scheduled toileting, treating the underlying cognitive or mobility issue).
| Symptom | Bladder overactivity (UUI) | Urethral underactivity (SUI) |
|---|---|---|
| Urgency (sudden, strong desire to void) | Yes | Not common |
| Frequency with urgency | Yes | Rarely |
| Leaking with coughing, sneezing, lifting | No | Yes |
| Volume of leakage per episode | Large if present | Usually small |
| Can reach the toilet after the urge hits | No, or just barely | Yes |
| Nocturnal incontinence (wet at night) | Yes | Rare |
| Nocturia | Usually | Seldom |
Big leak with a sudden urge = UUI. Small leak with a cough or a lift = SUI.If you remember nothing else about the two symptom tables, remember that one line.
The urethral sphincter is a mix of smooth and striated muscle, inside and outside the urethra, that holds enough resistance to keep urine in until the patient decides to void. Bladder (detrusor) contraction, both the normal kind and the pathologic kind, runs through postsynaptic muscarinic receptorsactivated by acetylcholine.
Detrusor smooth muscle carries mostly M2receptors by raw number, but M3is the one that actually does the work: it drives both the normal emptying contraction andthe involuntary contractions that cause UUI. That's why essentially every antimuscarinic used for OAB is functionally an anti-M3strategy, even the ones that aren't receptor-selective on paper. Block M3, relax the detrusor, reduce overactivity.
Separately, β3-adrenergic receptorson the detrusor do the opposite job through a different pathway: agonism activates adenylate cyclase, raises intracellular cAMP, activates protein kinase A, and that drops cytoplasmic calcium and phosphorylates myosin chains in a way that inhibitscontraction. Net effect is the same as blocking M3, smooth muscle relaxation, just reached through a completely separate receptor system. That's the entire rationale for mirabegron and vibegron as OAB alternatives to antimuscarinics.
Muscarinic receptors aren't just in the bladder. The same M3 blockade that relaxes the detrusor also hits salivary glands (dry mouth), the eye (blurred vision, mydriasis), the gut (constipation, delayed gastric emptying), and at high enough CNS penetration, cognition. None of the older antimuscarinics are bladder-selective in the body, only in intent. That's the whole reason the field moved toward non-oral routes (patch, gel) and toward β3-agonists, which don't touch muscarinic receptors at all and largely dodge this side effect profile.
UI in general happens from overactivity or underactivity of the urethra, the bladder, or both. SUIis urethral underactivity: the sphincter simply can't generate enough closure pressure to resist a cough, a sneeze, or a lift, so urine escapes during physical exertion. Overflow incontinence(chronic urinary retention) is the mirror image plus a bladder problem: urethral overactivity(obstruction) and/or bladder underactivity(can't generate enough contractile force) means the bladder fills past capacity and urine leaks past a distended system that can't empty itself. Common overflow causes are BPH, prostate cancer, and in women, cystocele or an overcorrected prior SUI surgery.
Treating SUI pharmacologically means improving urethral closure: stimulating α-adrenergic receptors in the bladder neck and proximal urethral smooth muscle, reinforcing the supportive tissue under the urethral epithelium (estrogen's role), or boosting serotonin/norepinephrine signaling in the micturition reflex pathway (duloxetine's role).
Antimuscarinics and β3-agonists relax the bladder, that's correct for UUI and would be actively harmful in overflow (it would only make retention worse). Nothing pharmacologic reliably fixes overflow, you have to fix the obstruction or the underactive detrusor underneath it.
Presentation tracks the underlying mechanism, which is exactly why history alone gets you most of the way to a type before you order a single test.
| Type | What they tell you |
|---|---|
| SUI | Leakage tied directly to physical activity: coughing, sneezing, laughing, lifting, exercise. Usually small volume, immediate. |
| UUI / OAB | Frequency, urgency, high-volume incontinence, nocturia, and nocturnal incontinence (wet pads or undergarments overnight). |
| Overflow | Lower abdominal fullness, hesitancy, straining to void, decreased or interrupted stream, sense of incomplete emptying. Can alsohave urgency, frequency, and abdominal pain, which is what makes it easy to mistake for OAB on symptoms alone. |
Overflow incontinence can present with urgency and frequency, the same words a UUI patient uses. The tell is the accompanying obstructive symptoms: hesitancy, weak stream, incomplete emptying. If you hear those alongside urgency, think overflow and check for retention before reaching for an antimuscarinic.
Start with a complete history and physical: abdominal exam to rule out a distended bladder, pelvic exam in women for prolapse or hormonal deficiency, genital and prostate exam in men, and a brief neuro check of the perineum and lower extremities.
UTI is the classic mimic of urgency UI. Treating a UTI as OAB delays the right treatment and can start a patient on an unnecessary antimuscarinic. Urinalysis and culture come before the OAB diagnosis sticks.
Goals:restore continence, cut the number of incontinence episodes, and prevent complications like skin breakdown, falls from nocturia, and recurrent UTIs, all while minimizing adverse effects and cost. Quality of life, caregiver burden, and reducing the risk of nursing home placement matter just as much as the raw episode count.
Behavioral interventions, lifestyle modification (fluid timing, caffeine and alcohol reduction, weight loss), scheduled voiding regimens, and pelvic floor muscle rehabilitation (Kegels) are first-line for SUI, UUI, andmixed UI. External neuromodulation, anti-incontinence devices (pessaries, absorbent products), and other supportive interventions round out the nonsurgical, nonpharmacologic options.
Surgeryrarely plays a role in initial management. It's reserved for cases where lifestyle compromise justifies an elective operation and nonsurgical therapy has proven ineffective or undesirable, or for secondary complications such as skin breakdown or infection.
None of the drugs in this chapter are curative or disease-modifying. They're symptom control, full stop. That's exactly why behavioral therapy isn't a "step before the real treatment," it's the foundation the drug gets added onto, and it should keep going even after a prescription starts.
Two drug classes, same end result (a quieter detrusor), reached two different ways: antimuscarinicsblock M3 directly, β3-agonistsrelax the muscle through a separate cAMP pathway. A systematic review of 94 randomized trials found similar, modest benefit across essentially all antimuscarinicscompared with placebo, so drug selection comes down to side-effect tolerance, comorbidities, drug interactions, and delivery preference, not expecting one to out-perform another.
Oxybutynin IRis the oldest and least expensive UUI treatment, and also the one patients quit most often. Adverse effects come from three separate mechanisms stacked on top of each other: nonurinary antimuscarinic effects (dry mouth, constipation, blurred vision, confusion, cognitive impairment, tachycardia), α-adrenergic inhibition (orthostatic hypotension), and H1 inhibition (sedation, weight gain).
Oxybutynin XL(extended-release) is better tolerated than IR, but full benefit can take up to 4 weeksafter starting or increasing the dose, so don't judge it early.
Oxybutynin TDS (patch)has similar efficacy to IR but far better tolerability, largely because the transdermal route skips first-pass hepatic metabolism, which is what generates the metabolite thought to drive dry mouth. Oxybutynin gelworks the same way and causes significantly less dry mouth than IR, though frail patients on long-term therapy still need anticholinergic monitoring.
Dry mouth incidence: oxybutynin IR 71%vs oxybutynin TDS 7%and gel 10%. Same drug, same mechanism, wildly different tolerability, purely a function of avoiding first-pass metabolism.
Tolterodineis a competitive muscarinic antagonist about as effective as oxybutynin IR but with a lower discontinuation rate. It's metabolized through CYP2D6 and 3A4, so elimination slows with CYP3A4 inhibitors: fluoxetine, sertraline, fluvoxamine, macrolide antibiotics, azole antifungals, and grapefruit juice all count. Most common adverse effects are dry mouth, dyspepsia, headache, constipation, and dry eyes. Maximum benefit isn't reached for up to 8 weeks. Tolterodine LAgives once-daily dosing with the same 8-week runway to full effect.
Fesoterodineis a prodrugthat's metabolized to the same active compound as tolterodine (5-hydroxymethyl tolterodine), and it's considered an alternative first-line agent for urinary frequency, urgency, or urge incontinence.
Trospium chlorideis a quaternary ammonium compound (poor CNS penetration), noninferior to oxybutynin IR with less dry mouth. Adverse effect frequency increases in patients age 75 and older. Take it 1 hour before meals or on an empty stomach; older patients on the IR formulation should take it at bedtime, and the ER formulation should be avoided entirely at ≥75 or CrCl ≤30 mL/min.
Solifenacinand darifenacinare second-generation antimuscarinics that improve both urinary symptoms and quality of life. Both interact with CYP3A4 inhibitors or inducers; darifenacin also goes through CYP2D6.
Not recommended:tricyclic antidepressants, propantheline, flavoxate, hyoscyamine, and dicyclomine. None of these outperform the drugs above, and all carry real potential for serious adverse effects, so there's no upside to reaching for them here.
Mirabegronwas approved in 2012 for adult OAB, with an extended-release granule formulation approved in 2021 for pediatric neurogenic detrusor overactivity. It has modest efficacy compared with placebo, not more effective than antimuscarinics, just differently tolerated. Most common adverse effects are hypertension, nasopharyngitis, UTI, and headache. It's also a moderate CYP2D6 inhibitor, worth remembering if the patient is on other 2D6 substrates.
Vibegronis the second β3-agonist, approved for OAB with urgency, frequency, and urgency incontinence. Its adverse effect profile in head-to-head tables is the cleanest of any OAB drug: dry mouth under 1%, constipation 2%, dizziness under 1%. Tablets can be crushed and mixed with applesauce for patients who struggle to swallow pills.
Frail, older, or cognitively vulnerable patients are exactly who benefits most from skipping antimuscarinics entirely. Cumulative anticholinergic exposure carries real cognitive risk in this population, and β3-agonists don't touch muscarinic receptors at all, so mirabegron or vibegron becomes a reasonable first choice rather than a fallback.
Botulinum toxin A temporarily paralyzes smooth or striated muscle and is indicated for detrusor overactivity from neurologic conditions and for OAB, positioned as third-linetherapy after behavioral and standard pharmacologic options fail. It's given as multiple intravesical injections directly into the bladder muscle without general anesthesia. Onset is 3-7 days, and effect fades over 6-8 months, meaning repeat injections are the norm. It increases bladder capacity and compliance and has shown quality-of-life improvement in refractory OAB, but adverse effects include dysuria, hematuria, UTI, and urinary retention in up to 20%, which is significant enough that patients need counseling about the possibility of needing to self-catheterize afterward.
| Drug | Brand | Initial dose | Usual range | Special population adjustment |
|---|---|---|---|---|
| Anticholinergics / Antimuscarinics | ||||
| Oxybutynin IR | Ditropan | 2.5 mg BID | 2.5-5 mg 2-4x/day | Titrate by 2.5 mg/day every 1-2 months; oral solution available |
| Oxybutynin XL | Ditropan XL | 5-10 mg daily | 5-30 mg daily | Adjust in 5-mg steps weekly; swallow whole |
| Oxybutynin TDS | Oxytrol / Oxytrol for Women (OTC) | 3.9 mg/day, 1 patch 2x/week | same | Apply every 3-4 days, rotate site |
| Oxybutynin gel 10% | Gelnique | 1 sachet (100 mg) topically daily | same | Apply to clean, dry, intact skin (abdomen, thigh, upper arm/shoulder); contains alcohol |
| Oxybutynin gel 3% | Gelnique 3% | 3 pumps (84 mg) topically daily | same | Same application sites as above |
| Tolterodine IR | Detrol | 1-2 mg BID | 1 mg BID with CYP3A4 inhibitors or renal/hepatic impairment | Avoid if CrCl <10 mL/min or severe hepatic impairment |
| Tolterodine LA | Detrol LA | 2-4 mg daily | 2 mg daily with CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir), Child-Pugh A/B, or CrCl 10-30 mL/min | Swallow whole; avoid if CrCl ≤10 mL/min or severe hepatic impairment |
| Trospium IR | Sanctura | 20 mg BID | 20 mg daily if age ≥75 or CrCl ≤30 mL/min | Take 1 h before meals or on empty stomach; ≥75 take at bedtime |
| Trospium ER | Sanctura XR | 60 mg daily | avoid if age ≥75 or CrCl ≤30 mL/min | Take 1 h before meals or empty stomach; swallow whole |
| Solifenacin | VESIcare | 5 mg daily | 5-10 mg daily | 5 mg daily with CYP3A4 inhibitors, CrCl ≤30 mL/min, or moderate hepatic impairment; avoid in severe hepatic impairment. Pediatric: weight-based suspension |
| Darifenacin ER | Enablex | 7.5 mg daily | 7.5-15 mg daily | 7.5 mg daily with potent CYP3A4 inhibitors or moderate hepatic impairment; avoid in severe hepatic impairment; titrate after ≥2 weeks; swallow whole |
| Fesoterodine ER | Toviaz | 4 mg daily | 4-8 mg daily | 4 mg daily with potent CYP3A4 inhibitors or CrCl ≤30 mL/min; avoid in severe hepatic impairment; prodrug, swallow whole |
| β3-Adrenergic Agonists | ||||
| Mirabegron ER | Myrbetriq | 25 mg daily | 25-50 mg daily | 25 mg daily if CrCl 15-29 mL/min or moderate hepatic impairment; avoid in ESRD / severe hepatic impairment; swallow whole |
| Vibegron | Gemtesa | 75 mg daily | same | avoid in ESRD ± dialysis or severe hepatic impairment; swallow whole, or crush and mix with applesauce |
SUI treatment aims at one goal: improve urethral closure. Three tools do that, each through a different mechanism, and none of them work as well or as reliably as the OAB drugs do for their target.
Local and systemic estrogen were historically the mainstay of SUI pharmacotherapy, but the evidence has flipped that on its head. A meta-analysis of 34 trialsfound that systemic estrogen, alone or combined with progesterone, actually worsens UIin postmenopausal women. Separately, a meta-analysis of 17 trialsof local (vaginal) estrogen found benefit for UI and OAB symptoms and some urodynamic parameters.
Only topical/vaginal estrogenshould be used for UI or OAB in postmenopausal women. Systemic estrogen is not just ineffective here, it makes incontinence worse. This is a frequently tested reversal of the "estrogen helps everything menopausal" assumption.
α-adrenergic receptor agonists stimulate smooth muscle in the bladder neck and proximal urethra, increasing closure pressure. Multiple open trials support their use in SUI, and combining an α-agonist with estrogen produces somewhat better clinical and urodynamic results than either alone.
Contraindications:hypertension, tachyarrhythmias, coronary artery disease, myocardial infarction, cor pulmonale, hyperthyroidism, renal failure, and narrow-angle glaucoma. This is a long list because you're systemically stimulating α-receptors, not just the ones in the urethra, so cardiovascular and pressure-sensitive conditions are where this gets risky.
Duloxetine is a dual serotonin-norepinephrine reuptake inhibitor approved in the US for depression and painful diabetic neuropathy. It's approved in many other countriesfor SUI, working by facilitating the bladder-to-sympathetic reflex pathway, which increases urethral and external sphincter tone during the storage phase. Six placebo-controlled trials showed it reduces incontinent episode frequency, reduces daily micturitions, lengthens the micturition interval, and improves quality-of-life scores, benefits that were statistically significant but clinically modest.
Monitor closely with concurrent CYP2D6 and CYP1A2substrates or inhibitors. Adverse effects, nausea, headache, insomnia, dizziness, constipation, dry mouth, are common enough to make adherence a real problem.
It has real trial evidence and international approval for this indication, but in the United States it's used off-label for SUI. Mixing that up with its US-approved indications (depression, diabetic neuropathy, fibromyalgia, chronic musculoskeletal pain) is a classic trap.
A huge chunk of real-world UI isn't a primary bladder or urethra problem at all, it's a side effect of something else the patient is taking. Always run the med list before starting a new incontinence drug.
| Medication class | Effect on continence |
|---|---|
| Diuretics, acetylcholinesterase inhibitors | Polyuria → urinary frequency, urgency |
| α-receptor antagonists | Urethral muscle relaxation → stress UI |
| α-receptor agonists | Urethral contraction → urinary retention (more common in men) |
| Calcium channel blockers | ↓ Bladder contractility → urinary retention |
| Narcotic analgesics | ↓ Bladder contractility → urinary retention |
| Sedative hypnotics | Functional incontinence via delirium, immobility |
| Antipsychotics | Anticholinergic effects → ↓ bladder contractility, retention |
| Anticholinergics | ↓ Bladder contractility → urinary retention |
| Tricyclic antidepressants | Both anticholinergic (retention) andα-antagonist (stress incontinence) effects at once |
| Alcohol | Polyuria → frequency, urgency |
| ACE inhibitors | ACEI cough can aggravate stress UI |
Tricyclics are the one class on this list that can cause two different kinds of incontinence at once: anticholinergic activity drives retention/overflow, while α-antagonism at the same time relaxes the urethra enough to cause stress incontinence. Worth remembering because it's an easy "which mechanism" trap.
Overflow secondary to benign or malignant prostatic hyperplasia may respond to pharmacotherapy, but the target is the obstruction(α-blockers, 5-alpha-reductase inhibitors for BPH), not the bladder itself. Nothing in the UUI or SUI drug lists belongs here.
Giving an antimuscarinic or β3-agonist to a patient with overflow incontinence or urinary retention relaxes the bladder further and worsens retention. Confirm the mechanism before prescribing, this is the single highest-stakes mix-up in the chapter.
| Parameter | When | Watching for |
|---|---|---|
| Incontinence episode frequency / pad use | Baseline, then every visit | Objective treatment response, not just "feeling better" |
| Anticholinergic adverse effects(dry mouth, constipation, blurred vision, cognition) | Every visit, especially in older adults | Dose-limiting side effects, cumulative cognitive burden with long-term use |
| Blood pressure | With mirabegron, and with any α-agonist for SUI | New or worsening hypertension |
| Renal and hepatic function | Baseline, periodically | Dose adjustment triggers for trospium, solifenacin, darifenacin, fesoterodine, mirabegron, tolterodine |
| Post-void residual / retention symptoms | If hesitancy, straining, or incomplete emptying develops on therapy | Iatrogenic overflow from over-relaxing the detrusor |
| Drug interactions (CYP2D6/3A4/1A2) | Every medication reconciliation | Tolterodine and darifenacin (2D6/3A4), solifenacin and fesoterodine (3A4), duloxetine (2D6/1A2), mirabegron as a 2D6 inhibitor of otherdrugs |
| Quality of life / caregiver burden | Periodically | Overall therapeutic success beyond raw episode counts |